%A Cao Chun, He Wenqi, Yan Jun %T Application of immune checkpoint inhibitors in the treatment of small cell lung cancer %0 Journal Article %D 2021 %J Journal of International Oncology %R 10.3760/cma.j.cn371439-20210305-00148 %P 747-750 %V 48 %N 12 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_11078.shtml} %8 2021-12-08 %X

The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.